Bioinformatic tools for cancer geneticists by Stankov Karmen
69
www.onk.ns.ac.yu/Archive    July 30, 2005
Bioinformatic tools for cancer geneticists
Karmen Stankov
ABSTRACT
Early detection is essential for the control and prevention of many diseases, particularly cancer, which
is the reason why the need for new disease markers with improved sensitivity and specificity continues
to grow. Utilization of sophisticated bioinformatic tools enables the increased specificity and a relative-
ly large quantity of high quality assays for any gene of interest. Understanding the molecular character-
istics of diseases, such as cancer and the detection of mutations or changes in gene expression pat-
terns that occur as a result of the disease, will bring researchers one step closer to achieving the pre-
dictive power needed for the development of new therapies, the design of clinical trials, and specific
patient treatment planning. Genetic screening is one of the fastest moving areas of medical science, par-
ticularly in oncology, and as more genes are cloned, and more disease-associated mutations discov-
ered, the workload is set to increase considerably with the utilization of bioinformatics tools used in inte-
gration and analysis of genomic, proteomic and metabolomic profiles of cancer.
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New horizons in oncogenomics 
T
he International Agency for Research on Cancer (IARC) has recently published its pre-
dictions for worldwide cancer incidence (1). They estimate that there will be almost 16
million new cases in the year 2020, an increase of 5.6 million (55%) over the figure for
2000, and 70% of these cases will be in developing countries.
In the past 30 years of cancer research, substantial progress has been made in basic and
strategic research, as evidenced by our improved understanding of the nature of cancer; but
less progress has been made in clinical and population research into cancer management,
as exemplified by the failure to significantly improve overall cancer control. This has led to
a burgeoning of translational research, to exploit experimental findings for the good of
humanity, as a whole and of cancer patient in particular. Most human genes can be simul-
taneously screened for potential disease associations by high throughput expression profil-
ing (e.g., by mRNA or SNP chips), as well as high throughput in silico analyses of data-
bases that contain genetic as well as clinical and functional information (2).
In the last few decades, advances in molecular biology and the equipment available for
research in this field have allowed the increasingly rapid sequencing of large portions of the
genomes of several species. In fact, to date, several bacterial genomes, as well as those of
some eukaryotes have been sequenced in full. The Human Genome Project, designed to
sequence all 24 of the human chromosomes, is also completed. Popular sequence data-
bases, such as GenBank and EMBL, have been growing at exponential rates (3,4). This del-
uge of information has necessitated the careful storage, organization and indexing of
sequence information. Information science has been applied to biology to produce the field
called bioinformatics. Bioinformatics is the field of science in which biology, computer sci-
ence, and information technology merge to form a single discipline. The ultimate goal of the
field is to enable the discovery of new biological insights as well as to create a global per-
spective from which unifying principles in biology can be discerned. Bioinformatics may be
defined as the integration of biological principles into the development of algorithms
involved in characterization of genomes and proteomes, and in identification of disease-
related genes (5,6).
In practice, the general term of bioinformatics covers two distinct areas: the science-based
aspect and the data management part. Bioinformatics refers to the access, handling, and
analysis of banks of scientific data that are available for scientists to feed into their own
research. Data management is rather more an extension of the traditional laboratory note-
book and allows researchers to seamlessly track, search, and archive large amounts of
experimental data between themselves and the other scientists working on the project. The
distinction between bioinformatics and data management, however, is becoming less
defined and the two functions have now effectively merged under the generic banner of
bioinformatics.
The main aim of bioinformatics is to provide systems to manage not only structured data,
such as documents and tables, but also unstructured data (rich data) like mass spectro-
metric and gene expression data. Every researcher and every laboratory is unique and the
situation is far more complicated than it may at first seem, because one is dealing not only
with enormous amounts of data, but also with a variety of types of data from many differ-
ent sources and different types and ages of technology.
The increasing availability of high-quality biological data from projects such as the sequenc-
ing and annotation of the human and other genomes, coupled with technological advances
in instrumentation, reagents, and software are transforming the way scientific discovery is
performed. As biomedicine and related disciplines begin to complement traditional labora-
tory research with information-based science, new opportunities exist for technology
providers to improve, expedite, and lower the cost of life-science discovery and develop-
ment programs. For example, the ability to combine genomic, proteomic, metabolic and
other biological information, with validated assays that address the full continuum of the
drug-discovery and development processes will help speed the development of safer, more
effective and better-targeted treatments for disease (8).
The most obvious current task of bioinformatics is to provide the essential connection for
the data generated by genomics and proteomics technologies. Handling massive amount of
data requires powerful integrated systems. Issues related to database inter-operability,
information presentation, data classification, and automatic extraction of information frompoorly organized sources (i.e., biological literature), are being addressed by different initia-
tives and large consortium. Even if complete solutions are still not at hand, very interesting
developments are taking place in some of these areas, including the development of cre-
ation of interchange standards in genomics, proteomics, protein interactions and metabol-
ic networks (9). The examples of utilization of the bioinformatic tools may be the studies of
protein folding and structure, structural genomics, functional analyses of regulatory genom-
ic regions, the pharmaceutical genomics, and associated studies.
The simplest tasks used in bioinformatics concern the creation and maintenance of data-
bases of biological information. Nucleic acid sequences (and the protein sequences derived
from them) comprise the majority of such databases. While the storage and organization of
millions of nucleotides is far from trivial, designing a database and developing an interface
whereby researchers can both access existing information and submit new entries is only
the beginning.
The most pressing tasks in bioinformatics involve the analysis of sequence information.
Computational biology is the name given to this process, and it involves the following:
- Finding the genes in the DNA sequences of various organisms 
- Developing methods to predict the structure and/or function of newly discovered proteins
and structural RNA sequences. 
- Clustering protein sequences into families of related sequences and the development of
protein models.
- Aligning similar proteins and generating phylogenetic trees to examine evolutionary rela-
tionships. 
The process of evolution has produced DNA sequences that encode proteins with very spe-
cific functions. It is possible to predict the three-dimensional structure of a protein using
algorithms that have been derived from our knowledge of physics, chemistry and most
importantly, from the analysis of other proteins with similar amino acid sequences.  Figure
1 summarizes the process by which DNA sequences are used to model protein structure.
Searching for genes
The collecting, organizing, and indexing of sequence information into a database, a chal-
lenging task in it, provides the scientist with a wealth of information, albeit of limited use.
The power of a database comes not from the collection of information, but in its analysis.
A sequence of DNA does not necessarily constitute a gene. It may constitute only a frag-
ment of a gene or alternatively, it may contain several genes. Luckily, in agreement with
evolutionary principles, scientific research to date has shown that all genes share common
elements. For many genetic elements, it has been possible to construct consensus
sequences, those sequences best representing the norm for a given class of organisms
(e.g., bacteria, eukaryotes). Common genetic elements include promoters, enhancers,
polyadenylation signal sequences, and protein binding sites. These elements have also
been further characterized into subelements. Genetic elements share common sequences,
and it is this fact that allows mathematical algorithms to be applied to the analysis of
sequence data. A computer program for finding genes should contain at least the elements
shown in Table 1.
Genome deciphered
Early in 2001, the duelling International Human Genome Sequencing Consortium (IHGSC)
(public) and Celera Corporation (private) groups published papers in Nature and Science
(10,11), describing the completion of so-called draft sequences. These sequences have
revolutionized molecular biology by largely eliminating the need to clone and sequence
genes involved in human health and disease. Instead of going to the bench, biologists now
go to the web to look up gene sequences in public online databases. But despite their
immediate usefulness, the draft sequences were far from perfect. Both drafts were missing
some 10% of the so-called euchromatin, the gene-rich portion of the genome, and some
30% of the genome as a whole (which includes the gene poor regions of heterochromatin).
The drafts contained hundreds of thousands of gaps, and had misassembled regions where
portions of the genome were flipped or misplaced. As a result, any large-scale analyses of
the genome, such as studies of the mechanisms of gene evolution or the long-range struc-
ture of the genome, had to contend with numerous uncertainties and artefacts. For exam-
ple, studies of pseudogenes, the dying remnants of genes that have accumulated mutations
that render them non-functional, had to contend with the possibility that any apparent
pseudogene was instead the result of a sequencing error. Since the publication of the
drafts, the IHGSC sequencing centres have quietly undertaken a laborious "finishing"
process, in which each gap in the draft was individually examined and subjected to a bat-
tery of steps involving cloning and re-sequencing stretches of DNA. The high-quality refer-
ence sequence was completed in April 2003, marking the end of the Human Genome
Project - 2 years ahead of the original schedule. Coincidentally, this was also the 50th
anniversary of Watson and Crick’s publication of DNA structure that launched the era of
molecular biology. Available to researchers worldwide, the human genome reference
sequence provides a magnificent and unprecedented biological resource that will serve
throughout the century as a basis for research and discovery and, ultimately, myriad prac-
tical applications. The sequence is already having an impact on finding genes associated
with human disease. The sequence announced today has just 341 gaps remaining, and
consists of contiguous runs of sequence averaging 38 million base pairs. The authors esti-
mate that the finished sequence covers 99% of the euchromatic portion of the genome and
that the overall error rate is less than 1 error per 100,000 base pairs. This substantially
exceeds the original goals for the project. The finishing procedure roughly doubled the total
time and cost of the project. Does it contribute anything new to our understanding of the
genome? It does indeed, and to prove the point the authors of the recent paper (12)
describe several large-scale analyses of the genome that would have been difficult to per-
form on the draft sequence. One analysis studied the processes of gene birth and death.
The authors find 1,183 human genes that show evidence of having been recently "born" by
a process of gene duplication and divergence. They also find 37 genes that seem to have
recently "died" by acquiring a mutation that rendered the gene non-functional. The resulting
pseudogene then slowly degrades and disappears. In a second analysis, the authors use
the finished sequence to map out segmental duplications, large regions of the genome that
have duplicated in recent evolution. They find that 5% of the genome is involved in seg-
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Figure 1. Modelling of protein structure
Table 1. The elements of a gene-seeking computer programmental duplications, and that the distribution of these regions varies widely across the chro-
mosomes. Knowing the nature and extent of such duplications is important for understand-
ing the evolution of the human genome, and for studying the many medically relevant dis-
orders that are involved in segmental duplications, such as DiGeorge syndrome and
Charcot-Marie-Tooth syndrome (13).
Principles in identifying disease genes
Few areas have moved as fast as human disease gene identification. Before 1980, very few
human genes had been identified as disease loci (most of these were for diseases with a
known biochemical basis, where it was possible to purify the gene product). In the 1980s,
advances in recombinant DNA technology allowed positional cloning and a consequent
increase in the number of disease genes identified. With the advent of PCR for linkage stud-
ies and mutation screening, the pace accelerated. Now, the human and other genome proj-
ects have made available a vast range of resources (maps, clones, sequences, expression
data, and phenotypic data), such as identifying novel genes is occurring on a weekly basis.
Figure 2 summarizes the possible routes to identify human disease genes, and shows that
there is significant interplay between clinical work, laboratory work, and computer analysis.
It should be noted that there is no standard or single pathway to success, but the key step
is to arrive at a plausible candidate gene, which can subsequently be tested for mutations
in affected people.
Individual techniques or strategies for identifying disease genes may be classified in princi-
ple as:
- Purely position-independent, using methods based on sequence homology or functional
complementation;
- Positional cloning, in which the identification of a disease gene is based solely on infor-
mation regarding its approximate chromosomal location;
In reality, most disease genes have being identified by a positional candidate strategy, using
a combination of positional and non-positional information. A purely position-independent
approach will rarely succeed because molecular pathology is too complicated, such that
predictions of the biochemical function of an unknown disease gene are often imprecise. A
purely positional approach is inefficient because candidate regions identified by positional
cloning usually contain dozens of genes.
Positional cloning may be defined as the identification and cloning of a specific human
gene, with chromosomal location as the only available information about the gene. Many
genetic disorders result from mutations in genes whose protein product and/or function is
unknown. Positional cloning is the only approach to the isolation of genes when there is no
biochemical or other data to suggest a likely candidate. The primary goal of a positional-
cloning study is to identify and characterize the mutation(s), variants, or polymorphisms
that give rise to specific disease phenotypes. The generally applied positional cloning strate-
gies provide a guide to the procedure, yet it is impossible to predict the exact flow for any
specific study. Many variables, such as the complexity of the disease phenotype (e.g., can-
cer), its frequency in the general population, its underlying genetic complexity, and the
physical nature of the DNA surrounding the disease gene may require repeating certain
steps many times.
There are four main strategies for identifying human genes:
- Functional cloning: information about the function of an unidentified gene is used to iso-
late the gene - either a gene product or a functional assay is required;
- Candidate gene approach: requires sufficient information about the molecular basis of
pathogenesis or the existence of a suitable animal or human model where the gene is
already known to be able to make an educated guess;
- Positional cloning: isolation of the gene knowing only its chromosomal location, which is
typically identified by linkage analysis. This approach includes the construction of physical
and genetic map of candidate region, identification of the genes within the region and inves-
tigation of each candidate gene until the disease gene is identified;
- Positional candidate approach: combines the positional and candidate gene approaches.
Candidate region may be already identified, usually by linkage, and genes known to map to
this region are then considered as candidates.
There is a considerable overlap between the four approaches. Ultimately, all four methods
are used to identify a candidate gene, which then has to be tested for association with the
disease.
All of the steps in positional cloning strategy involve the utilization of molecular biology
methods (such as cDNA library screening, cDNA selection, CpG island identification, exon
trapping, sequence analysis, STSs, ESTs, linkage, loss of heterozygosity, etc.) and bioin-
formatics methods. Our ability to find the genes involved in genetic susceptibility to many
diseases, including the cancer is increasing rapidly. The utilization of bioinformatic meth-
ods in cancer research already became a routine, owing to powerful analytical tools and the
completed human genome sequence information (14-16).
An essential feature of the positional candidate approach (and of successful disease gene
identification) is to prioritise candidate genes. This requires position-independent informa-
tion about their pattern of expression, likely function, or homology to genes implicated in
relevant mutants in model organisms. Any or all of following approaches can be used:
a) Expression pattern and function
From the list of genes that map to a candidate region (from databases such as Genome
Browser) (17), one would look for a gene that shows appropriate expression and/or func-
tion (or one that has homology to a human or non-human gene that displays these charac-
teristics). A good candidate gene should have an expression pattern consistent with the dis-
ease phenotype. Although expression need not be restricted to the affected tissue, the gene
should at least be expressed at the time and in the tissue where the pathology is seen.
Expression patterns can be tested by RT-PCR or Northern blotting, but the best method for
revealing exact expression patterns is in situ hybridisation against mRNA tissue sections.
Studying the pathology of a genetic disease often allows inference of possible function(s)
of the causative gene, which may allow good positional candidates to be selected.
Candidate genes may also be suggested on the basis of a close functional relationship to a
gene known to be involved in a similar disease, for example the genes encoding a receptor
and its ligand.
b) Homology to a relevant human gene or EST
Preliminary identification of transcripts often comes from analysis of genomic sequence
generated from the candidate region. If a sequence matches an unmapped EST (expressed
sequence tag) in the databases, the presence of an exon is suggested. Sometimes, a
sequence may show similarity to a known disease gene, and if the diseases are similar then
the new gene becomes a compelling candidate. However, attempting to prioritise candidate
genes on the basis of homology to other human genes may not always be successful, since
many diseases show extensive locus heterogeneity, i.e., the different genes involved in a
disease or group of diseases may not always be related in any obvious way, either struc-
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Figure 2. Target gene identification and validation is a multi-step processturally or functionally.
c) Homology to a relevant gene in a model organism
Since structural and functional homologies are known to extend across even very distantly
related species, it may often be more fruitful to select candidate genes by homology to
genes in model organisms. Not only do gene sequences show significant homology
between species, but also the pathways are often highly conserved. It should be noted that
mammals might have several pathways corresponding to a single path in lower organisms.
A very powerful method of selecting good candidate genes is therefore to search databas-
es for evidence of homologous genes in other model organisms. Additionally, in the mouse,
though not in non-mammalian species, the likely chromosomal location of the human
ortholog can often be predicted from mouse mapping data, which allows prediction of as
yet uncharacterised positional candidates.
The challenge of protein modelling
There are a myriad of steps following the location of a gene locus to the realization of a
three-dimensional model of the protein that it encodes (9).
The first step is the location of transcriptional start and stop. A proper analysis to locate a
genetic locus will usually have already pinpointed at least the approximate sites of the tran-
scriptional start and stop. Such an analysis is usually sufficient in determining protein struc-
ture. It is the start and end codons for translation that must be determined with accuracy.
The second phase is the identification of the position of the translational start and stop. The
first codon in a messenger RNA sequence is almost always AUG. While this reduces the
number of candidate codons, the reading frame of the sequence must also be taken into
consideration. 
There are six reading frames possible for a given DNA sequence, three on each strand,
which must be considered, unless further information is available. Since genes are usually
transcribed away from their promoters, the definitive location of this element can reduce the
number of possible frames to three. There is not a strong consensus between different
species surrounding translation start codons. Therefore, location of the appropriate start
codon will include a frame in which they are not apparent abrupt stop codons. Knowledge
of a protein’s predicted molecular mass can assist this analysis. Incorrect reading frames
usually predict relatively short peptide sequences. Therefore, it might seem deceptively
simple to ascertain the correct frame in bacteria such is frequently the case. However,
eukaryotes add a new obstacle to this process: detection of intron/exon splice sites.
In eukaryotes, the reading frame is discontinuous at the level of the DNA because of the
presence of introns. Unless one is working with a cDNA sequence in analysis, these introns
must be spliced out and the exons joined to give the sequence that actually codes for the
protein. 
Intron/exon splice sites can be predicted on the basis of their common features. Most
introns begin with the nucleotides GT and end with the nucleotides AG. There is a branch
sequence near the downstream end of each intron involved in the splicing event. There is a
moderate consensus around this branch site. 
With the completed primary amino acid sequence in hand, the challenge of modelling the
three-dimensional structure of the protein awaits as the fourth step. This process uses a wide
range of data and CPU-intensive computer analysis. Most often, one is only able to obtain a
rough model of the protein, and several conformations of the protein may exist that are equal-
ly probable. The best analyses will utilize data from all the sources shown in Table 2.
All of this information is used to determine the most probable locations of the atoms of the
protein in space and bond angles. Graphical programs can then use this data to depict a
three-dimensional model of the protein on the two-dimensional computer screen.
Cancer target discovery using proteomics
With the development of exceptionally sensitive instruments every few years, progress in
the field of proteomics has been rapid although there are still a few areas where current
technology is either not sensitive or fast enough to be useful (18). Identifying non-abundant
proteins, determining millisecond physiologic responses and elucidating the expression of
proteins as dynamic transitions occur in cells, organs and individuals are three such areas
where there are more questions than answers.
For many diseases, the pancreatic and breast cancer are amongst the most striking exam-
ples, a diagnosis tends to occur in the advanced stages of the disease and the prognosis
is very poor. Determining the molecular profiles to stratify subtypes of patients’ diseases
would prove the opportunity for earlier intervention and targeted treatment.
The development of mass spectrometers capable of providing data for peptide sequencing
has enabled the acquisition of protein data in high throughput, giving rise to industrialized
proteomics. Proteomics on such a scale offers a rapid route of discovery of new targets for
pharmaceutical intervention (19,20).
Introduction to molecular biology databases
Recent years have seen an explosive growth in biological data, which is often not published
anymore in a conventional sense, but deposited in a database. Sequence data from mega-
sequencing projects may not even be linked to a conventional publication. This trend and
the need for computational analyses of the data made databases essential tools for biolog-
ical research. Under the URL of Swiss Institute of Bioinformatics, it is possible to find a
comprehensive web document that lists many databases and many other information
sources for molecular biologists (21).
A biological database is a large, organized body of persistent data, usually associated with
computerised software designed to update, query, and retrieve components of the data
stored within the system. A simple database might be a single file containing many records,
each of which includes the same set of information.
Services that abstract the scientific literature began to make their data available in machine-
readable form in the early 1960s. However, up to date, none of the abstracting services has
a complete coverage. The best known is MEDLINE and now PUBMED, abstracting mainly
the medical literature. MEDLINE/ PUBMED is best accessible through NCBI’s ENTREZ (22,
23). EMBASE is a commercial product for the medical literature. Most of the bibliographi-
cal databases are only available through commercial database vendors.
Taxonomic databases are rather controversial since the soundness of the taxonomic clas-
sifications done by one taxonomist will be directly questioned by the next taxonomist.
Various efforts are going on to create a taxonomy source (e.g. "The Tree of Life" project;
"Species 2000"; Integrated Taxonomic Information System, etc.) (24-26). The most gener-
ally useful taxonomic database is that maintained by NCBI (27). That hierarchical taxono-
my is used by the Nucleotide Sequence Databases, SWISS-PROT and TrEMBL, and is cre-
ated by an informal group of experts.
The International Nucleotide Sequence Database Collaboration is a joint production of the
nucleotide sequence database by the EBI (European Bioinformatics Institute), DDBJ (DNA
Data Bank of Japan), and NCBI (National Centre for Biotechnology Information) (28-30). In
Europe, the vast majority of the nucleotide sequence data produced is collected, organized
and distributed by the EMBL Nucleotide Sequence Database located at the EBI, Cambridge,
UK, an Outstation of the European Molecular Biology Laboratory (EMBL) in Heidelberg,
Germany (31). The nucleotide sequence databases are data repositories, accepting nucle-
ic acid sequence data from the community and making it freely available. The databases
strive for completeness, with the aim of recording every publicly known nucleic acid
sequence. These data are heterogeneous; they vary with respect to the source of the mate-
Stankov K.
72
www.onk.ns.ac.yu/Archive    July 30, 2005
Table 2. The sources of data used for protein analysesrial (e.g. genomic versus cDNA), the intended quality (e.g. finished versus single pass
sequences), the extent of sequence annotation and the intended completeness of the
sequence relative to its biological target (e.g., complete versus partial coverage of a gene
or a genome). EMBL, NCBI, and DDBJ automatically update each other every 24 hours with
the new sequences they collected or updated. The result is that they contain the same infor-
mation, except for sequences that have been added in the last 24 hours. Each entry in the
database must have a unique identifier that is a string of letters and/or numbers that only
that record has. This unique identifier, which is known as the accession number, can be
quoted in the scientific literature, as it will never change. As the accession number must
always remain the same, another code is used to indicate the different versions due to
sequence corrections. Therefore, it should be always taken care to quote both the unique
identifier and the version number, when referring to records in a nucleotide sequence data-
base.
For organisms of major interest to geneticists, there is a long history of conventionally pub-
lished catalogues of genes or mutations. In the past few years, most of these have been
made available in an electronic form, and a variety of new databases have been developed.
There are several databases for genomes of Escherichia coli (E. coli Genetic Stock Centre),
Saccharomyces (MIPS yeast database), Drosophila melanogaster (FlyBase),
Caenorhabditis elegans, or mouse (Mouse Genome Database), used in the functional study
of house keeping and other evolutionary conserved genes in humans and human diseases
(32-37). Two major databases for human genes and genomics are in existence. McKusick’s
Mendelian Inheritance in Man (MIM) is a catalogue of human genes and genetic disorders
and is available in an online form (OMIM) from the NCBI (38). The Genome Database (GDB)
is the major human genome database including both molecular and mapping data (39).
Both OMIM and GDB include information on genetic variation in humans, but there is also
the Sequence Variation Database project at the EBI, with links to many single sequence vari-
ation databases at the EBI, and to the SRS (Sequence Retrieval System) interface to many
human mutation databases (40). The GeneCards resource at the Weizmann Institute inte-
grates information about human genes from a variety of databases, including GDB, OMIM,
SWISS-PROT and the nucleotide sequence databases (41). GENATLAS also provides a
database of human genes, with links to diseases and maps (42). The goal of the National
Cancer Institute’s Cancer Genome Anatomy Project (CGAP) is to determine the gene
expression profiles of normal, precancerous, and cancer cells, leading eventually to
improved detection, diagnosis, and treatment for the patient. By collaborating with scien-
tists worldwide, such as the Ludwig Institute for Cancer Research and Lund University,
CGAP seeks to increase its scientific expertise and expand its databases for the benefit of
all cancer researchers (43).
A relatively new database has been created by EnsEMBL, a joint project between EMBL-EBI
and the Sanger Centre that strives to develop a software system, which produces and main-
tains automatic annotation on eukaryotic genomes. Human data are available now, with
worm and mouse added later (44).
The protein sequence databases are the most comprehensive source of information on pro-
teins. It is necessary to distinguish between universal databases covering proteins from all
species and specialized data collections storing information about specific families or
groups of proteins, or about the proteins of a specific organism. Two categories of univer-
sal protein databases can be discerned: simple archives of sequence data and annotated
databases where additional information has been added to the sequence record. 
The Protein Information Resource (PIR) was established in 1984 by the National Biomedical
Research Foundation (NBRF) as a successor of the original NBRF Protein Sequence
Database, developed over a 20-year period (45). Since 1988, the database has been main-
tained by PIR-International, collaboration between the NBRF, The Munich Information Centre
for Protein Sequences (MIPS) and the Japan International Protein Information Database
(JIPID) (46). The PIR database is portioned into four sections, according to the degree of
classification of protein entries, with section four that includes sequences identified as not
naturally occurring or expressed. PIR provides also some degree of cross-referencing to
other biomolecular databases by linking to the DDBJ/EMBL/GenBank nucleotide sequence
databases, GDB, FlyBase, and OMIM.
SWISS-PROT is an annotated protein sequence database established in 1986 and main-
tained collaboratively by the Swiss Institute of Bioinformatics (SIB) and the EMBL
Outstation, The European Bioinformatic Institute (EBI) (47-49). It strives to provide a high
level of annotation, a minimal level of redundancy, a high level of integration with other
molecular databases as well as extensive external documentation. Each entry in SWISS-
PROT gets thoroughly analysed and annotated by biologists ensuring a high standard of
annotation and maintaining the quality of the database (50). SWISS-PROT contains data
that originate from a wide variety of organisms; the latest release number 46 from February
1, 2005 contains 168297 annotated sequence entries from more than 8826 different
species. SWISS-PROT includes in addition to citations about sequencing work also refer-
ences to other scientific work like 3-D structure determination, mutagenesis, and detection
of post-translational modifications and variants.
There is a tremendous increase of sequence data due to technological advances (such as
sequencing machines), the use of new biochemical methods (such as PCR and gene chip
technology), as well as the implementation of projects to sequence complete genomes
(51). These advances have brought along an enormous flood of sequence information.
Maintaining the high quality of SWISS-PROT requires, for each entry, a time-consuming
process that involves the extensive use of sequence analysis tools along with detailed cre-
ation steps by expert annotators, is the rate-limiting step in the production of the database.
A supplement to SWISS-PROT was created in 1996, since it is vital to make new sequences
available as quickly as possible without relaxing the high editorial standards of SWISS-
PROT. This supplement, the TrEMBL (Translation of EMBL nucleotide sequence database),
consists of computer-annotated entries derived from the translation of all coding sequences
(CDS) in the EMBL nucleotide sequence database, except for those already included in
SWISS-PROT. All EMBL nucleotide sequence database divisions are regularly scanned for
new or updated CDS features. These are translated to TrEMBLnew entries, which are in
SWISS-PROT format. This section is organized in six subsections:
1. Immunoglobulins and T-cell receptors (file name Immuno.dat)
2. Synthetic sequences (file name Synth.dat)
3. Small fragments (file name Small.dat), a subsection with protein fragments with less then
eight amino acids.
4. Patent application sequences (file name Patent.dat). Coding sequences captured from
patent applications.
5. CDS not coding for real proteins (file name Pseudo.dat).
6. Truncated proteins (file name Truncated.dat), which result from events like mutations
introducing a stop codon leading to the truncation of protein product.
Amongst the specialized proteins databases, the ENZYME database presents an annotated
extension of the Enzyme Commission’s publication, linked to SWISS-PROT (52). There are
also databases of enzyme properties - BRENDA, Ligand Chemical Database for Enzyme
Reactions (LIGAND), and the Database of Enzymes and Metabolic Pathways (EMP) (53,
54). BRENDA, LIGAND and EMP are searchable via SRS at the EBI. LIGAND is linked to the
metabolic pathways in Kyoto Encyclopaedia of Genes and Genomes (55, 56).
The number of known protein structures is increasing very rapidly and these are available
through the Protein Data Bank (PDB) (57). The Nucleic Acid Database (NDB) is the data-
base for structural information about nucleic acid molecules (58). There is also a database
of structures of "small" molecules, of interest to biologists concerned with protein-ligand
interactions, from the Cambridge Crystallographic Data Centre (59).
CONCLUSION
The rapidly emerging field of bioinformatics promises to lead to advances in understanding
basic biological processes, and in turn, advances in the diagnosis, treatment and preven-
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www.onk.ns.ac.yu/Archive   July 30, 2005tion of many genetic diseases. Bioinformatics has transformed the biomedical disciplines
from purely lab-based science to information sciences as well. Increasingly, biological
studies begin with a scientist conducting a vast numbers of database and Web site search-
es to formulate specific hypotheses or design large-scale experiments. The implications
behind this change, for both science and medicine are staggering.
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